Voyager CEO Al Sandrock supports the FDA's use of accelerated approval for severe diseases but argues it must be coupled with industry accountability. He praises Amelix for voluntarily pulling its ALS drug after a failed confirmatory trial, framing such responsible actions as essential for maintaining the FDA's willingness to be flexible with approvals based on surrogate endpoints.

Progress in drug development often hides inside failures. A therapy that fails in one clinical trial can provide critical scientific learnings. One company leveraged insights from a failed study to redesign a subsequent trial, which was successful and led to the drug's approval.

The FDA's willingness to consider a regulatory path for Clean's ALS drug based on neurofilament data is a pivotal shift. This reverses its previous hesitance and signals a new potential pathway for accelerated approvals across many neurodegenerative diseases where clinical endpoints are slow to measure.

Neurofilament light chain (NFL) is an undisputed biomarker for neurodegeneration. Consistently negative readings indicate cells are dying less, providing a pure, objective signal that a therapy is working. This data alone should be enough to meet the 'probable benefit' standard for an Accelerated Approval (AA).

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

The fastest, cheapest path to drug approval involves showing a small survival benefit in terminally ill patients. This economic reality disincentivizes the longer, more complex trials required for early-stage treatments that could offer a cure.

Re-analysis revealed the drug's efficacy was concentrated in patients 65 and younger, extending survival by 17.1 months. This effect was missed in the original trials because it was diluted by the non-responsive older population, whose declined immune systems could not fully engage with the treatment.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

By granting priority review to Agios's sickle cell drug after it missed its primary endpoint, the FDA signals a major shift. For severe rare diseases with high unmet need, the agency now appears willing to approve drugs based on activity signals and safety, prioritizing patient access over statistically proven efficacy in pivotal trials.